Description
COEMPAKEN Tablets 12.5/1000mg (14’s) offer a robust and comprehensive approach to managing Type 2 Diabetes Mellitus. Each film-coated tablet combines Empagliflozin 12.5mg, a Sodium-Glucose Co-Transporter 2 (SGLT2) inhibitor, and Metformin HCl 1000mg, a biguanide. Empagliflozin works by increasing the excretion of glucose from the body via the kidneys, thereby lowering blood sugar levels. It also provides significant benefits in reducing the risk of cardiovascular death, hospitalization for heart failure, and the progression of chronic kidney disease in adults with Type 2 Diabetes. Metformin complements this action by reducing glucose production in the liver and enhancing the body’s sensitivity to insulin. This synergistic dual action provides powerful glycemic control when diet and exercise alone are insufficient. Consistent daily use, as prescribed by a healthcare professional, is essential for optimizing blood sugar levels and realizing the full cardiovascular and renal protective benefits. This is a prescription-only medication.
